期刊文献+

Expression change of nuclear receptor corepressor (NCoR) in androgen independence prostate cancer and its clinical significance

Expression change of nuclear receptor corepressor (NCoR) in androgen independence prostate cancer and its clinical significance
暂未订购
导出
摘要 Objective:To explore the expression of nuclear receptor corepressor (NCoR) in androgen independence prostate cancer (AIPC) and its clinical significance. Methods:The expression of NCoR and androgen receptor (AR) in prostatie tissues, from 15 cases with AIPC, 20 cases with androgen dependence prostate cancer (ADPC) and 20 cases with benign prostatic hyperplasia (BPH), was detected by immunohistoehemistry respectively. Results:The expression of NCoR was observed mainly in the nucleus and slightly in the nucleus. The positive cell percentage of NCoR in AIPC was significantly lower than that in ADPC and BPH (P〈0. 01). The NCoR expression was significantly lower in low differentiation prostate cancer (Pca) than that in high differentiation Pca (P〈0. 05). The rate of NCoR expression was significantly higher in low stage Pca than that in high stage Pca (P〈0. 05). AR, expressing in the nucleus, was found to be negative in one case of AIPC, while was strongly expressed in other cases of AIPC, and all eases of ADPC and BPH. Conclusion: The transition to AIPC of Pea may be correlated with the decrease of NCoR protein. Objective:To explore the expression of nuclear receptor corepressor (NCoR) in androgen independence prostate cancer (AIPC) and its clinical significance. Methods:The expression of NCoR and androgen receptor (AR) in prostatic tissues, from 15 cases with AIPC, 20 cases with androgen dependence prostate cancer (ADPC) and 20 cases with benign prostatic hyperplasia (BPH), was detected by immunohistochemistry respectively. Results:The expression of NCoR was observed mainly in the nucleus and slightly in the nucleus. The positive cell percentage of NCoR in AIPC was significantly lower than that in ADPC and BPH (P<0.01). The NCoR expression was significantly lower in low differentiation prostate cancer (Pca) than that in high differentiation Pca (P<0.05). The rate of NCoR expression was significantly higher in low stage Pca than that in high stage Pca (P<0.05). AR, expressing in the nucleus, was found to be negative in one case of AIPC, while was strongly expressed in other cases of AIPC, and all cases of ADPC and BPH. Conclusion: The transition to AIPC of Pca may be correlated with the decrease of NCoR protein.
出处 《Journal of Medical Colleges of PLA(China)》 CAS 2005年第4期241-244,共4页 中国人民解放军军医大学学报(英文版)
关键词 prostate cancer nuclear receptor corepressor IMMUNOHISTOCHEMISTRY 基因表达 核感受器辅抑制物 男性激素 前列腺癌
  • 相关文献

参考文献8

  • 1[1]Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase Ⅱ clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group [J]. J Clin Oncol, 1999; 17(11): 3461.
  • 2[2]Heinzel T, Lavinsky RM, Mullen TM et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression [J]. Nature, 1997; 387(6628): 43.
  • 3[3]Chen JD,Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors [J]. Nature, 1995; 377 (6548): 454.
  • 4[4]Cheng S, Brzostek S, Lee SR et al. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor [J]. Mol Endocrinol, 2002; 16 (7): 1492.
  • 5[5]List HJ, Smith CL, Rodriguez O et al. Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels: an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter [J]. Exp Cell Res, 1999; 252(2): 471.
  • 6[6]Huang ZQ,Li J, Wong J et al. AR possesses an intrinsic hormone-independent transcriptional activity [J]. Mol Endocrinol, 2002; 16(5): 924.
  • 7[7]Gregory CW, Johnson RT, Mohler JL et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen [J]. Cancer Res, 2001; 61(7): 2892.
  • 8[8]Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer [J]. J Natl Cancer Inst, 2003; 95(5): 353.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部